Premium
‘ProtecTion’ from overtreatment: does a randomized trial finally answer the key question in localized prostate cancer?
Author(s) -
Wang Luke L.,
Wallis Christopher J.D.,
Sathianathen Niranjan,
Lawrentschuk Nathan,
Murphy Declan G.,
Nam Robert,
Moon Daniel
Publication year - 2017
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13734
Subject(s) - medicine , prostate cancer , library science , cancer , computer science
randomized trial finally answer the key question in localized prostate cancer? Luke L. Wang*, Christopher J.D. Wallis, Niranjan Sathianathen, Nathan Lawrentschuk , Declan G. Murphy**, Robert Nam and Daniel Moon* *Australian Urology Associates, Malvern, Department of Surgery, Central Clinical School, Monash University, Melbourne, Vic., Australia, Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, Division of Cancer Surgery, Peter MacCallum Cancer Centre, Department of Surgery, Austin Health, University of Melbourne, Melbourne, and **Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Vic., Australia